- As part of its efforts to streamline operations in India, Sandoz is closing an API plant in Mumbai.
- Sandoz, the generics division of Novartis, has emphasized that it remains committed to India.
- Sandoz has two additional plants in India, which will remain open.
Sandoz has emphasized that it will remain committed to India, despite the fact that it is closing the Mumbai plant. It has another API facility in Mahad, in addition to a facility in Kalwe, where oral solid dosage products are produced. Both of these facilities are located in the Maharashtra state and are very productive, with over 3 billion tablets produced.
The plant that is closing employs 170 workers, all of whom will lose their jobs.